CASTLEFORD, England, December 18 /PRNewswire/ -- Teva UK Limited has launched generic co-beneldopa capsules in a variety of strengths. The company says that they are the first generic to reach the market.

We're delighted to be launching co-beneldopa capsules, said Kim Innes, Commercial Director, Teva UK Limited. This product fits well with our range and strengthens our position as the UK's leading generics supplier. It comes hot on the heels of diamorphine hydrochloride (HCL) powder for injection, oxcarbazepine tablets and topiramate tablets which were added to our product portfolio during the last quarter she added.

Co-beneldopa is a dopaminergic drug indicated for treatment of symptoms of Parkinson's disease(1). It is a generic version of Madopar(R) (co- beneldopa) made by Roche. It is available immediately in the award-winning Teva 360 livery, which is designed to aid patient safety, in the following strengths and at these prices(2):

- Co-Beneldopa capsules 50 mg / 12.5 mg x 100 GBP5.36 - Co-Beneldopa capsules 100 mg / 25 mg x 100 GBP7.47 - Co-Beneldopa capsules 200 mg / 50 mg x 100 GBP12.74

At the moment over 50% of scripts are written by brand. If all scripts were written and dispensed generically the potential saving to the NHS would be over GBP341k annually(3). said Kim Innes, Commercial Director, Teva UK Limited.


1) Co-beneldopa SmPC

2) Teva price list December 2009

3) Based on current price and reimbursement data - IMS Xponent NPA Audit Sept 2009

About Teva UK Limited: Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd which has 38,000 employees based in 70 countries around the world.

Note to Editors:

A picture accompanying this release is available through the PA Photowire. It can be downloaded from or viewed at or


CONTACT: For media enquiries, telephone the Teva Communications team on+44-(0)1977-628500, or email